The purpose of the Meet with Series events at JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings.
On November 1st, AbbVie Ventures Director Charles Kunsch will be in attendance to give an overview presentation about the company's key areas of interest and to meet one-on-one with companies that have been accepted after applying online.
AbbVie Ventures investment areas of interest include:
- Oncology - interested in targeting multiple tumor types with an emphasis on mechanisms related to apoptosis, epigenetics, DNA replication/repair, immune-oncology, modulation of the tumor/host interaction and technologies for ADCs and identification of new targets
- Neuroscience –focus is on disease modifying approaches for neurodegenerative diseases including Alzheimer's, Parkinson's, Multiple Sclerosis and ALS)
- Immunology/Autoimmune Disease – interests lie in disease modifying approaches that significantly improve upon the current standard of care in rheumatology (RA, OA Ankylosing Spondylitis), Gastrointestinal disease (Crohn's, Ulcerative Colitis) and Dermatology (Psoriasis, Atopic Dermatitis)
- Curative approaches for the treatment of chronic viral diseases such as Hepatitis B Virus are also of interest
- New technology platforms that lead to transformational new therapeutic modalities are also of interest
Following the presentation, don't miss this opportunity to introduce yourself to Charles during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with AbbVie will provide an intimate forum to discuss your company
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking Lunch
1:00-5:00 PM | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on October 13th.
AbbVie Ventures Participating Representative:
Charles Kunsch | Director, AbbVie Ventures
Chuck has over twenty five years of experience in biomedical R&D, business development and corporate venture capital investing. Since 2013, Chuck has been a member of AbbVie's Venture team and is based in Boston, MA where his focus is on early-stage investments in life science companies. Chuck is responsible for sourcing, evaluating and transacting venture investments and early-stage business development partnerships and is a board observer to several AbbVie portfolio companies. Prior to joining the Ventures team, Chuck served as a Director in Abbott's Global External Research group where he was responsible for the identification, assessment, and development of early-stage partnerships across Abbott's therapeutic areas. Before joining Abbott in 2009, he served as Vice President of Discovery at AtheroGenics, Inc leading teams that brought several programs into clinical development for cardiovascular disease, diabetes, rheumatoid arthritis and asthma. Before joining AtheroGenics, Dr. Kunsch started his career in biotech as one of the first scientists with Human Genome Sciences where he led a team of scientists to fully sequence the genomes of several medically important bacterial pathogens. Dr. Kunsch obtained his B.S. in Biological Sciences from Drexel University and Ph.D. from Penn State's College of Medicine in Microbiology and Immunology. He performed his postdoctoral work at the Roche Institute of Molecular Biology under the mentorship of Craig Rosen. Dr. Kunsch is an inventor on more than 30 patents and has authored more than 125 peer-reviewed manuscripts, scientific reviews and book chapters.
Connect with Charles:
Presentation & Lunch
CA$ 35 | General Public
CA$ 50 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on October 31st (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on October 13th. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
JLABS @ Toronto
MaRS Centre, West Tower
661 University Ave, Suite 1300 [13th Floor]
When & Where
JLABS @ Toronto
JLABS, part of Johnson & Johnson Innovation, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.